FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294770642> ?p ?o ?g. }

• W4294770642 endingPage "872" @default.
• W4294770642 startingPage "872" @default.
• W4294770642 abstract "Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow dysplasia along with anemia, neutropenia, or thrombocytopenia. MDS are associated with an increased risk of acute myeloid leukemia (AML). The yearly incidence of MDS is approximately 4 per 100 000 people in the United States and is higher among patients with advanced age.MDS are characterized by reduced numbers of peripheral blood cells, an increased risk of acute myeloid leukemia transformation, and reduced survival. The median age at diagnosis is approximately 70 years, and the yearly incidence rate increases to 25 per 100 000 in people aged 65 years and older. Risk factors associated with MDS include older age and prior exposures to toxins such as chemotherapy or radiation therapy. MDS are more common in men compared with women (with yearly incidence rates of approximately 5.4 vs 2.9 per 100 000). MDS typically has an insidious presentation, consisting of signs and symptoms associated with anemia, thrombocytopenia, and neutropenia. MDS can be categorized into subtypes that are associated with lower or higher risk for acute myeloid leukemia transformation and that help with therapy selection. Patients with lower-risk MDS have a median survival of approximately 3 to 10 years, whereas patients with higher-risk disease have a median survival of less than 3 years. Therapy for lower-risk MDS is selected based on whether the primary clinical characteristic is anemia, thrombocytopenia, or neutropenia. Management focuses on treating symptoms and reducing the number of required transfusions in patients with low-risk disease. For patients with lower-risk MDS, erythropoiesis stimulating agents, such as recombinant humanized erythropoietin or the longer-acting erythropoietin, darbepoetin alfa, can improve anemia in 15% to 40% of patients for a median of 8 to 23 months. For those with higher-risk MDS, hypomethylating agents such as azacitidine, decitabine, or decitabine/cedazuridine are first-line therapy. Hematopoietic cell transplantation is considered for higher-risk patients and represents the only potential cure.MDS are diagnosed in approximately 4 per 100 000 people in the United States and are associated with a 5-year survival rate of approximately 37%. Treatments are tailored to the patient's disease characteristics and comorbidities and range from supportive care with or without erythropoiesis-stimulating agents for patients with low-risk MDS to hypomethylating agents, such as azacitidine or decitabine, for patients with higher-risk MDS. Hematopoietic cell transplantation is potentially curative and should be considered for patients with higher-risk MDS at the time of diagnosis." @default.
• W4294770642 created "2022-09-06" @default.
• W4294770642 creator A5055740968 @default.
• W4294770642 creator A5089377441 @default.
• W4294770642 date "2022-09-06" @default.
• W4294770642 modified "2023-10-13" @default.
• W4294770642 title "Diagnosis and Treatment of Myelodysplastic Syndromes" @default.
• W4294770642 cites W1527383154 @default.
• W4294770642 cites W165520502 @default.
• W4294770642 cites W187238933 @default.
• W4294770642 cites W1889574318 @default.
• W4294770642 cites W1964227719 @default.
• W4294770642 cites W1979616743 @default.
• W4294770642 cites W1985823023 @default.
• W4294770642 cites W1996887331 @default.
• W4294770642 cites W2017468796 @default.
• W4294770642 cites W2027950772 @default.
• W4294770642 cites W2034863154 @default.
• W4294770642 cites W2057858099 @default.
• W4294770642 cites W2064416627 @default.
• W4294770642 cites W2066053804 @default.
• W4294770642 cites W2082646723 @default.
• W4294770642 cites W2099071696 @default.
• W4294770642 cites W2106082819 @default.
• W4294770642 cites W2108739937 @default.
• W4294770642 cites W2113271378 @default.
• W4294770642 cites W2118120560 @default.
• W4294770642 cites W2118771330 @default.
• W4294770642 cites W2121533623 @default.
• W4294770642 cites W2122811690 @default.
• W4294770642 cites W2124135166 @default.
• W4294770642 cites W2125347906 @default.
• W4294770642 cites W2126448969 @default.
• W4294770642 cites W2126816979 @default.
• W4294770642 cites W2130963430 @default.
• W4294770642 cites W2131593570 @default.
• W4294770642 cites W2131639268 @default.
• W4294770642 cites W2133682816 @default.
• W4294770642 cites W2135667425 @default.
• W4294770642 cites W2149858388 @default.
• W4294770642 cites W2162942332 @default.
• W4294770642 cites W2189916683 @default.
• W4294770642 cites W2326726820 @default.
• W4294770642 cites W2339658711 @default.
• W4294770642 cites W2406284768 @default.
• W4294770642 cites W2467917196 @default.
• W4294770642 cites W2570962027 @default.
• W4294770642 cites W2584597412 @default.
• W4294770642 cites W2585106732 @default.
• W4294770642 cites W2606218280 @default.
• W4294770642 cites W2613190989 @default.
• W4294770642 cites W2674757831 @default.
• W4294770642 cites W2705856695 @default.
• W4294770642 cites W2742767772 @default.
• W4294770642 cites W2756224392 @default.
• W4294770642 cites W2767866960 @default.
• W4294770642 cites W2784405738 @default.
• W4294770642 cites W2900418013 @default.
• W4294770642 cites W2922692686 @default.
• W4294770642 cites W2992213152 @default.
• W4294770642 cites W2994929704 @default.
• W4294770642 cites W2998901800 @default.
• W4294770642 cites W3010095701 @default.
• W4294770642 cites W3015984203 @default.
• W4294770642 cites W3016476526 @default.
• W4294770642 cites W3123615891 @default.
• W4294770642 cites W3127892484 @default.
• W4294770642 cites W3164945230 @default.
• W4294770642 cites W3165899249 @default.
• W4294770642 cites W3172203368 @default.
• W4294770642 cites W3203124293 @default.
• W4294770642 cites W4226144246 @default.
• W4294770642 cites W4232476584 @default.
• W4294770642 cites W4240411959 @default.
• W4294770642 cites W4242027161 @default.
• W4294770642 cites W4245499371 @default.
• W4294770642 cites W4252676322 @default.
• W4294770642 cites W4252830541 @default.
• W4294770642 cites W4253801986 @default.
• W4294770642 cites W4283271244 @default.
• W4294770642 cites W4362054083 @default.
• W4294770642 doi "https://doi.org/10.1001/jama.2022.14578" @default.
• W4294770642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36066514" @default.
• W4294770642 hasPublicationYear "2022" @default.
• W4294770642 type Work @default.
• W4294770642 citedByCount "24" @default.
• W4294770642 countsByYear W42947706422022 @default.
• W4294770642 countsByYear W42947706422023 @default.
• W4294770642 crossrefType "journal-article" @default.
• W4294770642 hasAuthorship W4294770642A5055740968 @default.
• W4294770642 hasAuthorship W4294770642A5089377441 @default.
• W4294770642 hasConcept C120665830 @default.
• W4294770642 hasConcept C121332964 @default.
• W4294770642 hasConcept C126322002 @default.
• W4294770642 hasConcept C187212893 @default.
• W4294770642 hasConcept C2776694085 @default.
• W4294770642 hasConcept C2777063308 @default.
• W4294770642 hasConcept C2778248108 @default.

• next